Search

Your search keyword '"Takahashi, Shunji"' showing total 14 results
Start Over Author "Takahashi, Shunji" Language undetermined
14 results on '"Takahashi, Shunji"'

3. Additional file 1 of Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis

Author

Inari, Hitoshi, Teruya, Natsuki, Kishi, Miki, Horii, Rie, Akiyama, Futoshi, Takahashi, Shunji, Ito, Yoshinori, Ueno, Takayuki, Iwase, Takuji, and Ohno, Shinji

Abstract

Additional file 1: Table S1 Clinicopathological characteristics of patients with breast cancer. Table S3 Summary of initial treatment after IM–SC LN recurrence. Table S4 Subtypes and treatment of patients with IM-SC LN recurrence without DM according to pathological LN status at primary tumor. Table S5 Multivariate analysis of prognostic factors related to DDFS in patients with IM-SC LN recurrence without DM.

Published
2020
Full Text
View/download PDF

4. Additional file 3: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Subjects
embryonic structures, digestive system diseases
Abstract

Table S2. The relationship between CDX2 expression and overall survival in patients undergoing preoperative chemotherapy. (DOC 80 kb)

Published
2018
Full Text
View/download PDF

5. Additional file 6: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Subjects
embryonic structures, digestive system diseases
Abstract

Table S5. Association between KRAS and CDX2 expression status in patients with colorectal cancer after potentially curative liver metastasectomy. (DOC 53 kb)

Published
2018
Full Text
View/download PDF

6. Additional file 4: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Subjects
embryonic structures, digestive system diseases
Abstract

Table S3. Site of recurrence in patients with CDX2-high and CDX2-low colorectal cancer after potentially curative liver metastasectomy. (DOC 78 kb)

Published
2018
Full Text
View/download PDF

7. Additional file 5: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Abstract

Table S4. Association between mismatch repair-deficient and CDX2 expression status in patients with colorectal cancer after potentially curative liver metastasectomy. (DOC 53 kb)

Published
2018
Full Text
View/download PDF

8. Additional file 3: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Subjects
embryonic structures, digestive system diseases
Abstract

Table S2. The relationship between CDX2 expression and overall survival in patients undergoing preoperative chemotherapy. (DOC 80 kb)

Published
2018
Full Text
View/download PDF

9. Additional file 4: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Subjects
embryonic structures, digestive system diseases
Abstract

Table S3. Site of recurrence in patients with CDX2-high and CDX2-low colorectal cancer after potentially curative liver metastasectomy. (DOC 78 kb)

Published
2018
Full Text
View/download PDF

10. Additional file 5: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Abstract

Table S4. Association between mismatch repair-deficient and CDX2 expression status in patients with colorectal cancer after potentially curative liver metastasectomy. (DOC 53 kb)

Published
2018
Full Text
View/download PDF

11. Additional file 6: of Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Author

Shigematsu, Yasuyuki, Inamura, Kentaro, Yamamoto, Noriko, Mise, Yoshihiro, Saiura, Akio, Ishikawa, Yuichi, Takahashi, Shunji, and Kanda, Hiroaki

Subjects
embryonic structures, digestive system diseases
Abstract

Table S5. Association between KRAS and CDX2 expression status in patients with colorectal cancer after potentially curative liver metastasectomy. (DOC 53 kb)

Published
2018
Full Text
View/download PDF

12. Additional file 1: of Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Author

Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun, Jae-Lyun Lee, Jinsoo Chung, Lim, Ho, Hsi Wu, Chang, Yen, Azad, Arun, Davis, Ian, Carrasco-Alfonso, Marlene, Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, and Motzer, Robert

Subjects
3. Good health
Abstract

Conduct of NCT00720941 and NCT01147822 and timing of key study events. Protocol amendment 4 authorized inclusion of patients from NCT01147822 for safety and efficacy analyses. FPFV = first patient first visit. Data from Motzer RJ et al. [8]. Conduct of trials NCT00720941 and NCT01147822. (PDF 111Â kb)

13. Additional file 1: of Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Author

Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun, Jae-Lyun Lee, Jinsoo Chung, Lim, Ho, Hsi Wu, Chang, Yen, Azad, Arun, Davis, Ian, Carrasco-Alfonso, Marlene, Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, and Motzer, Robert

Subjects
3. Good health
Abstract

Conduct of NCT00720941 and NCT01147822 and timing of key study events. Protocol amendment 4 authorized inclusion of patients from NCT01147822 for safety and efficacy analyses. FPFV = first patient first visit. Data from Motzer RJ et al. [8]. Conduct of trials NCT00720941 and NCT01147822. (PDF 111Â kb)

Catalog

Books, media, physical & digital resources
See catalog results